Trevi Therapeutics, Inc. Gains 44.58%
Trevi Therapeutics, Inc. (TRVI:NASDAQ) shot up at $3.6, representing a gain of 44.6%. On Thu, Dec 12, 2024, TRVI:NASDAQ hit a New 2-Week High of $3.6. The stock appeared on our News Catalysts scanner on Thu, Dec 12, 2024 at 10:07 AM in the 'MISCELLANEOUS' category. From Fri, Nov 29, 2024, the stock recorded 33.33% Up Days and 30.00% Green Days
The stock spiked on Thu, Dec 12, 2024 at $4.6 with a volume of 63M+.
About Trevi Therapeutics, Inc. (TRVI:NASDAQ)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Top 10 Gainers:
- MSP Recovery Inc. (LIFW:NASDAQ), 103.77%
- Palisade Bio Inc. (PALI:NASDAQ), 68.57%
- SEALSQ Corp. (LAES:NASDAQ), 60.87%
- Himax Technologies, Inc. (HIMX:NASDAQ), 44.93%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 44.58%
- WISeKey International Holding AG (WKEY:NASDAQ), 36.67%
- MKDWELL Tech Inc. (MKDW:NASDAQ), 36.26%
- Canoo Inc. (GOEV:NASDAQ), 34.62%
- Jupiter Neurosciences Inc. (JUNS:NASDAQ), 33.65%
- UTime Limited (WTO:NASDAQ), 32.72%